10 Citations (Scopus)

Abstract

Preclinical Research Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that is frequently characterized by the constitutive expression of the oncogenic protein BCR-ABL tyrosine kinase. Tyrosine kinase inhibitors (TKIs) targeting breakpoint cluster region-ABL are the first-line therapy for most CML patients and have drastically improved the prognosis of CML. However, some CML patients are unresponsive to TKI treatment, and a notable proportion of initially responsive patients develop drug resistance. Several molecular pathways have been correlated with resistance to TKI treatment, however, the exact mechanism of developing drug resistance remains ambiguous. Recently, microRNAs (miRNAs) have been implicated in the progression of CML and the development of resistance to TKI treatment based on their important regulatory function in cell homeostasis, and the deregulation observed in the initiation and progression of many leukemia subtypes. In this review, we summarize some of the major discoveries regarding miRNAs in CML, and their relevance as biomarkers for diagnosis, disease progression, and drug sensitivity.

Original languageEnglish (US)
Pages (from-to)278-285
Number of pages8
JournalDrug Development Research
Volume76
Issue number6
DOIs
StatePublished - Sep 1 2015

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Biomarkers
MicroRNAs
Drug Resistance
Therapeutics
Disease Progression
Leukemia
Homeostasis
Research
Pharmaceutical Preparations
Neoplasms
Proteins

Keywords

  • biomarkers
  • chronic myelogenous leukemia
  • drug response
  • Imatinib
  • microRNA

ASJC Scopus subject areas

  • Drug Discovery

Cite this

MiRNAs as Biomarkers in Chronic Myelogenous Leukemia. / Kotagama, Kasuen; Chang, Yung; Mangone, Marco.

In: Drug Development Research, Vol. 76, No. 6, 01.09.2015, p. 278-285.

Research output: Contribution to journalArticle

@article{4ac21d26ba7a4f1ab47678e66a7ef222,
title = "MiRNAs as Biomarkers in Chronic Myelogenous Leukemia",
abstract = "Preclinical Research Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that is frequently characterized by the constitutive expression of the oncogenic protein BCR-ABL tyrosine kinase. Tyrosine kinase inhibitors (TKIs) targeting breakpoint cluster region-ABL are the first-line therapy for most CML patients and have drastically improved the prognosis of CML. However, some CML patients are unresponsive to TKI treatment, and a notable proportion of initially responsive patients develop drug resistance. Several molecular pathways have been correlated with resistance to TKI treatment, however, the exact mechanism of developing drug resistance remains ambiguous. Recently, microRNAs (miRNAs) have been implicated in the progression of CML and the development of resistance to TKI treatment based on their important regulatory function in cell homeostasis, and the deregulation observed in the initiation and progression of many leukemia subtypes. In this review, we summarize some of the major discoveries regarding miRNAs in CML, and their relevance as biomarkers for diagnosis, disease progression, and drug sensitivity.",
keywords = "biomarkers, chronic myelogenous leukemia, drug response, Imatinib, microRNA",
author = "Kasuen Kotagama and Yung Chang and Marco Mangone",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/ddr.21266",
language = "English (US)",
volume = "76",
pages = "278--285",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - MiRNAs as Biomarkers in Chronic Myelogenous Leukemia

AU - Kotagama, Kasuen

AU - Chang, Yung

AU - Mangone, Marco

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Preclinical Research Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that is frequently characterized by the constitutive expression of the oncogenic protein BCR-ABL tyrosine kinase. Tyrosine kinase inhibitors (TKIs) targeting breakpoint cluster region-ABL are the first-line therapy for most CML patients and have drastically improved the prognosis of CML. However, some CML patients are unresponsive to TKI treatment, and a notable proportion of initially responsive patients develop drug resistance. Several molecular pathways have been correlated with resistance to TKI treatment, however, the exact mechanism of developing drug resistance remains ambiguous. Recently, microRNAs (miRNAs) have been implicated in the progression of CML and the development of resistance to TKI treatment based on their important regulatory function in cell homeostasis, and the deregulation observed in the initiation and progression of many leukemia subtypes. In this review, we summarize some of the major discoveries regarding miRNAs in CML, and their relevance as biomarkers for diagnosis, disease progression, and drug sensitivity.

AB - Preclinical Research Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that is frequently characterized by the constitutive expression of the oncogenic protein BCR-ABL tyrosine kinase. Tyrosine kinase inhibitors (TKIs) targeting breakpoint cluster region-ABL are the first-line therapy for most CML patients and have drastically improved the prognosis of CML. However, some CML patients are unresponsive to TKI treatment, and a notable proportion of initially responsive patients develop drug resistance. Several molecular pathways have been correlated with resistance to TKI treatment, however, the exact mechanism of developing drug resistance remains ambiguous. Recently, microRNAs (miRNAs) have been implicated in the progression of CML and the development of resistance to TKI treatment based on their important regulatory function in cell homeostasis, and the deregulation observed in the initiation and progression of many leukemia subtypes. In this review, we summarize some of the major discoveries regarding miRNAs in CML, and their relevance as biomarkers for diagnosis, disease progression, and drug sensitivity.

KW - biomarkers

KW - chronic myelogenous leukemia

KW - drug response

KW - Imatinib

KW - microRNA

UR - http://www.scopus.com/inward/record.url?scp=84941259839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941259839&partnerID=8YFLogxK

U2 - 10.1002/ddr.21266

DO - 10.1002/ddr.21266

M3 - Article

VL - 76

SP - 278

EP - 285

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 6

ER -